Agilent Technologiesvs.Illumina
A vs ILMN · both in Life science tools, part of the Medicine, pharma & life science value chain: Instruments, reagents and equipment for research, development and production.
Agilent Technologies is about 1.2× larger than Illumina by market cap; Agilent Technologies trades at the lower P/E (33.3 vs 49.3); year to date, Illumina leads (+101.7% vs +24.3%).
Side by side
| A | ILMN | |
|---|---|---|
| Market cap | $48B | $40.7B |
| Price | $170.54 | $278.17 |
| Today | +1.4% | +5.1% |
| Return YTD | +24.3% | +101.7% |
| Return 1Y | +22.0% | +170.6% |
| Since June 26, 2026 | +25.4% | +57.6% |
| P/E | 33.3 | 49.3 |
| P/S | 6.5 | 9.1 |
| P/B | 6.5 | 14.3 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Agilent TechnologiesA
Laboratory analysis is the business: LC/MS and other analytical instruments, sold with the consumables and diagnostic reagents that keep them running.
Full A profile →IlluminaILMN
DNA sequencing machines and the reagents they consume, for research and clinical genomics.
Full ILMN profile →More A & ILMN comparisons
Other head-to-heads in the Life science tools segment.